Zydus gets USFDA nod to market anti-epileptic drug in US

New Delhi, Oct 17 (UNI) Cadila Healthcare Ltd today said it has received approval from the United States Food and Drug Authority (USFDA) to market its anti-epileptic Zonisamide capsules.

The company will market the drug in strengths of 25 mg, 50 mg and 100 mg through its US subsidiary Zydus Pharmaceuticals Inc.

The branded sales of the capsules in the US market is estimated at 178 million dollars in 2005 as per IMS.

This approval marks l7th ANDA approval for the group since the commencement of filing process in FY 2003-04. So far the group has filed 41 ANDAs and 45 DMFs.

UNI CS KR RK1516